Zura Bio Ltd (ZURA)

Feb 24, 2025

Zura Bio to Present at the Leerink Partners Global Healthcare Conference - Yahoo Finance

Feb 24, 2025

Feb 16, 2025

Analysts Set Zura Bio Limited (NASDAQ:ZURA) Price Target at $15.80 - Defense World

Feb 16, 2025

Feb 14, 2025

Zura Bio Limited (NASDAQ:ZURA) Shares Purchased by SG Americas Securities LLC - Defense World

Feb 14, 2025

Feb 13, 2025

Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates - ADVFN

Feb 13, 2025

Feb 12, 2025

ZURA stock touches 52-week low at $1.44 amid market shifts - Investing.com Nigeria

Feb 12, 2025

Feb 11, 2025

ZURA stock touches 52-week low at $1.44 amid market shifts By Investing.com - Investing.com South Africa

Feb 11, 2025

Feb 03, 2025

After losing 43% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain - Simply Wall St

Feb 03, 2025

Jan 26, 2025

Zura Bio (NASDAQ:ZURA) vs. Aptose Biosciences (NASDAQ:APTO) Critical Contrast - Defense World

Jan 26, 2025

Jan 25, 2025

Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA) - MSN

Jan 25, 2025

Jan 23, 2025

Cantor Fitzgerald Predicts Zura Bio FY2025 Earnings - MarketBeat

Jan 23, 2025

Jan 22, 2025

We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth - Yahoo Finance

Jan 22, 2025

Jan 21, 2025

Barclays PLC Purchases 56,757 Shares of Zura Bio Limited (NASDAQ:ZURA) - Defense World

Jan 21, 2025

Jan 13, 2025

ZURA stock touches 52-week low at $1.97 amid market shifts - Investing.com Canada

Jan 13, 2025

Jan 13, 2025

Corporate Overview January 2025 Advancing Dual Pathway Biologic Candidates: Addressing Unmet Needs in Autoimmune and Inflammatory Diseases - Marketscreener.com

Jan 13, 2025

Jan 13, 2025

Zura Bio Highlights Strategic Goals and Clinical Advances - TipRanks

Jan 13, 2025

Jan 06, 2025

Barclays PLC Raises Stock Holdings in Zura Bio Limited (NASDAQ:ZURA) - Defense World

Jan 06, 2025

Jan 02, 2025

State Street Corp Increases Position in Zura Bio Limited (NASDAQ:ZURA) - Defense World

Jan 02, 2025

Dec 27, 2024

Reversal Of Fortune For Zura Bio Insiders Who Made A US$1.01m Purchase - Simply Wall St

Dec 27, 2024

Dec 25, 2024

Zura Bio’s (ZURA) Neutral Rating Reaffirmed at HC Wainwright - Defense World

Dec 25, 2024

Dec 24, 2024

Zura Bio shares outlook positive as Phase 2 TibuSURE study evaluates key SSc complications - Investing.com India

Dec 24, 2024

Dec 24, 2024

Zura Bio begins Phase 2 study for systemic sclerosis treatment By Investing.com - Investing.com South Africa

Dec 24, 2024

Dec 24, 2024

Zura Bio initiates Phase II systemic sclerosis treatment trial - Yahoo Finance

Dec 24, 2024

Dec 23, 2024

Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis - Quantisnow

Dec 23, 2024

Dec 18, 2024

17,442 Shares in Zura Bio Limited (NASDAQ:ZURA) Acquired by The Manufacturers Life Insurance Company - Defense World

Dec 18, 2024

Dec 14, 2024

Zura Bio FY2025 EPS Forecast Increased by Leerink Partnrs - Defense World

Dec 14, 2024

Dec 13, 2024

Zura Bio FY2025 EPS Forecast Boosted by Leerink Partnrs - MarketBeat

Dec 13, 2024

Dec 13, 2024

Cantor Fitzgerald Reaffirms Overweight Rating for Zura Bio (NASDAQ:ZURA) - Defense World

Dec 13, 2024

Dec 03, 2024

Zura Bio Limited (NASDAQ:ZURA) Receives $15.80 Average PT from Analysts - Defense World

Dec 03, 2024

Nov 30, 2024

Zura Bio Limited (NASDAQ:ZURA) Receives $15.80 Average Target Price from Analysts - MarketBeat

Nov 30, 2024

Nov 28, 2024

Zura Bio Limited (NASDAQ:ZURA) Short Interest Update - Defense World

Nov 28, 2024

Nov 25, 2024

Zura Bio : to Present at the Piper Sandler 36th Annual Healthcare Conference Form 8 K - Marketscreener.com

Nov 25, 2024

Nov 25, 2024

Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference - Yahoo Finance

Nov 25, 2024

Nov 25, 2024

Zura Bio to Present at Piper Sandler Healthcare Conference, Showcasing Immunology Pipeline - StockTitan

Nov 25, 2024

Nov 22, 2024

We're Hopeful That Zura Bio (NASDAQ:ZURA) Will Use Its Cash Wisely - Simply Wall St

Nov 22, 2024

Nov 20, 2024

HC Wainwright Reaffirms “Neutral” Rating for Zura Bio (NASDAQ:ZURA) - Defense World

Nov 20, 2024

Nov 18, 2024

HC Wainwright Reaffirms "Neutral" Rating for Zura Bio (NASDAQ:ZURA) - MarketBeat

Nov 18, 2024

Nov 15, 2024

GREAT POINT PARTNERS LLC Reduces Stake in Zura Bio Ltd - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

ADAR1 Capital Management, LLC Acquires New Stake in Zura Bio Ltd - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Zura Bio advances Phase 2 study for systemic sclerosis treatment - Investing.com

Nov 14, 2024

Nov 14, 2024

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis - Yahoo Finance

Nov 14, 2024

Nov 13, 2024

HC Wainwright Has Positive Outlook for Zura Bio Q3 Earnings - MarketBeat

Nov 13, 2024

Nov 09, 2024

Guggenheim maintains Buy on Zura Bio, target steady at $15 - Investing.com India

Nov 09, 2024

Nov 08, 2024

Guggenheim maintains Buy on Zura Bio, target steady at $15 By Investing.com - Investing.com UK

Nov 08, 2024

Nov 06, 2024

Q3 Earnings Forecast for Zura Bio Issued By Leerink Partnrs - MarketBeat

Nov 06, 2024

Nov 06, 2024

Zura Bio (NASDAQ:ZURA) Stock Rating Upgraded by Leerink Partnrs - Defense World

Nov 06, 2024

Nov 05, 2024

Piper Sandler sets price target on Zura Bio shares, cites positive trial data - Investing.com

Nov 05, 2024

Nov 05, 2024

Leerink Partners initiates Zura Bio stock with Outperform rating, $15 target - Investing.com

Nov 05, 2024